Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 543

1.

Patient-Centered Outcomes and Key Study Procedure Finalization in the Pilot Feasibility Gout Randomized Trial: Comparative Feasibility Study in GOUt, CHerry Extract Versus Diet Modification (Mini-GOUCH).

Singh JA, Willig AL, Darnell B, Green C, Morgan S, Weiss R, Saag KG, Cutter G, McGwin G.

J Clin Rheumatol. 2019 Mar 12. doi: 10.1097/RHU.0000000000001018. [Epub ahead of print]

PMID:
30870252
2.

Cortical Activation Elicited by Subthalamic Deep Brain Stimulation Predicts Postoperative Motor Side Effects.

Romeo A, Dubuc DM, Gonzalez CL, Patel ND, Cutter G, Delk H, Guthrie BL, Walker HC.

Neuromodulation. 2019 Mar 7. doi: 10.1111/ner.12901. [Epub ahead of print]

PMID:
30844131
3.

Evolution of clinical trials in multiple sclerosis.

Zhang Y, Salter A, Wallström E, Cutter G, Stüve O.

Ther Adv Neurol Disord. 2019 Feb 21;12:1756286419826547. doi: 10.1177/1756286419826547. eCollection 2019. Review.

4.

The prevalence of MS in the United States: A population-based estimate using health claims data.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG; US Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035. Epub 2019 Feb 15.

PMID:
30770430
5.

A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.

Nelson LM, Wallin MT, Marrie RA, Culpepper WJ, Langer-Gould A, Campbell J, Buka S, Tremlett H, Cutter G, Kaye W, Wagner L, Larocca NG; United States Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):469-480. doi: 10.1212/WNL.0000000000007044. Epub 2019 Feb 15. Review.

PMID:
30770422
6.

A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout.

Singh JA, Green C, Morgan S, Willig AL, Darnell B, Saag KG, Weiss R, Cutter G, McGwin G.

J Clin Rheumatol. 2019 Jan 23. doi: 10.1097/RHU.0000000000001004. [Epub ahead of print]

PMID:
30702450
7.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25.

PMID:
30692052
8.

Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Mowry EM, Marrie RA.

Mult Scler Relat Disord. 2019 Apr;29:86-93. doi: 10.1016/j.msard.2019.01.031. Epub 2019 Jan 24.

PMID:
30690340
9.

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.

Kennedy RE, Cutter GR, Fowler ME, Schneider LS.

JAMA Netw Open. 2018 Nov 2;1(7):e184080. doi: 10.1001/jamanetworkopen.2018.4080.

10.

Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA.

Neurol Clin Pract. 2018 Dec;8(6):472-481. doi: 10.1212/CPJ.0000000000000523.

PMID:
30588376
11.

Rationale and design of a single-blind, randomised controlled trial of exercise training for managing learning and memory impairment in persons with multiple sclerosis.

Sandroff BM, Motl RW, Bamman M, Cutter GR, Bolding M, Rinker JR, Wylie GR, Genova H, DeLuca J.

BMJ Open. 2018 Dec 14;8(12):e023231. doi: 10.1136/bmjopen-2018-023231.

12.

Implementation of Occupational Sun Safety at a 2-Year Follow-Up in a Randomized Trial: Comparison of Sun Safe Workplaces Policy Intervention to Attention Control.

Buller DB, Walkosz BJ, Buller MK, Wallis A, Andersen PA, Scott MD, Meenan RT, Cutter GR.

Am J Health Promot. 2018 Nov 26:890117118814398. doi: 10.1177/0890117118814398. [Epub ahead of print]

PMID:
30477333
13.

Gender differences in prednisone adverse effects: Survey result from the MG registry.

Lee I, Kaminski HJ, McPherson T, Feese M, Cutter G.

Neurol Neuroimmunol Neuroinflamm. 2018 Oct 15;5(6):e507. doi: 10.1212/NXI.0000000000000507. eCollection 2018 Nov.

14.

Use of eHealth and mHealth technology by persons with multiple sclerosis.

Marrie RA, Leung S, Tyry T, Cutter GR, Fox R, Salter A.

Mult Scler Relat Disord. 2019 Jan;27:13-19. doi: 10.1016/j.msard.2018.09.036. Epub 2018 Oct 2.

PMID:
30296732
15.

Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era.

Kister I, Bacon TE, Cutter GR.

Ther Adv Neurol Disord. 2018 Sep 11;11:1756286418793613. doi: 10.1177/1756286418793613. eCollection 2018.

16.

Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials.

Bamman MM, Cutter GR, Brienza DM, Chae J, Corcos DM, DeLuca S, Field-Fote E, Fouad MN, Lang CE, Lindblad A, Motl RW, Perna CG, Reisman D, Saag KM, Savitz SI, Schmitz KH, Stevens-Lapsley J, Whyte J, Winstein CJ, Michel ME.

Arch Phys Med Rehabil. 2018 Dec;99(12):2637-2648. doi: 10.1016/j.apmr.2018.08.173. Epub 2018 Aug 24.

PMID:
30148997
17.

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.

Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBD Program.

Epilepsy Behav. 2018 Oct;87:131-136. doi: 10.1016/j.yebeh.2018.07.020. Epub 2018 Aug 9.

18.

Sun Safe Workplaces: Effect of an Occupational Skin Cancer Prevention Program on Employee Sun Safety Practices.

Walkosz BJ, Buller D, Buller M, Wallis A, Meenan R, Cutter G, Andersen P, Scott M.

J Occup Environ Med. 2018 Nov;60(11):900-997. doi: 10.1097/JOM.0000000000001427.

PMID:
30095593
19.

Clinical trials in multiple sclerosis: milestones.

Zhang Y, Salter A, Cutter G, Stϋve O.

Ther Adv Neurol Disord. 2018 Jul 9;11:1756286418785499. doi: 10.1177/1756286418785499. eCollection 2018. Review.

20.

An introduction to Mendelian randomization with applications in neurology.

Allman PH, Aban IB, Tiwari HK, Cutter GR.

Mult Scler Relat Disord. 2018 Aug;24:72-78. doi: 10.1016/j.msard.2018.06.017. Epub 2018 Jun 20. Review.

PMID:
29960142
21.

Phase-III, randomized controlled trial of the behavioral intervention for increasing physical activity in multiple sclerosis: Project BIPAMS.

Motl RW, Sandroff BM, Wingo BC, McCroskey J, Pilutti LA, Cutter GR, Bollaert RE, McAuley E.

Contemp Clin Trials. 2018 Aug;71:154-161. doi: 10.1016/j.cct.2018.06.017. Epub 2018 Jun 27.

PMID:
29959105
22.

Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution.

Weis CA, Aban IB, Cutter G, Kaminski HJ, Scharff C, Grießmann BW, Deligianni M, Kayser K, Wolfe GI, Ströbel P, Marx A.

PLoS One. 2018 Jun 13;13(6):e0197435. doi: 10.1371/journal.pone.0197435. eCollection 2018.

23.

Divergent effects of AKI to CKD models on inflammation and fibrosis.

Black LM, Lever JM, Traylor AM, Chen B, Yang Z, Esman SK, Jiang Y, Cutter GR, Boddu R, George JF, Agarwal A.

Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F1107-F1118. doi: 10.1152/ajprenal.00179.2018. Epub 2018 Jun 13.

PMID:
29897282
24.

Mortality in neuromyelitis optica is strongly associated with African ancestry.

Mealy MA, Kessler RA, Rimler Z, Reid A, Totonis L, Cutter G, Kister I, Levy M.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 7;5(4):e468. doi: 10.1212/NXI.0000000000000468. eCollection 2018 Jul. No abstract available.

25.

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators.

Mult Scler. 2018 May 1:1352458518773511. doi: 10.1177/1352458518773511. [Epub ahead of print]

PMID:
29761737
26.

Understanding and Preventing Loss to Follow-up: Experiences From the Spinal Cord Injury Model Systems.

Kim H, Cutter GR, George B, Chen Y.

Top Spinal Cord Inj Rehabil. 2018 Spring;24(2):97-109. doi: 10.1310/sci2402-97.

27.

DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial.

Ben Ali W, Voisine P, Olsen PS, Jeanmart H, Noiseux N, Goeken T, Satishchandran V, Cademartiri F, Cutter G, Veerasingam D, Brown C, Emmert MY, Perrault LP.

Open Heart. 2018 Apr 13;5(1):e000780. doi: 10.1136/openhrt-2018-000780. eCollection 2018.

28.

Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 1: Effects on Real-World Function.

Mark VW, Taub E, Uswatte G, Morris DM, Cutter GR, Adams TL, Bowman MH, McKay S.

Neurorehabil Neural Repair. 2018 Mar;32(3):223-232. doi: 10.1177/1545968318761050.

29.

Declining Financial Capacity in Mild Cognitive Impairment: A Six-Year Longitudinal Study.

Martin RC, Gerstenecker A, Triebel KL, Falola M, McPherson T, Cutter G, Marson DC.

Arch Clin Neuropsychol. 2019 Mar 1;34(2):152-161. doi: 10.1093/arclin/acy030.

PMID:
29617705
30.

A survey of dietary characteristics in a large population of people with multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox RJ, Marrie RA.

Mult Scler Relat Disord. 2018 May;22:12-18. doi: 10.1016/j.msard.2018.02.019. Epub 2018 Feb 27.

PMID:
29510324
31.

Factors associated with excessive sitting time in multiple sclerosis.

Sasaki JE, Motl RW, Cutter G, Marrie RA, Tyry T, Salter A.

Mult Scler Relat Disord. 2018 Apr;21:71-77. doi: 10.1016/j.msard.2018.02.009. Epub 2018 Feb 10.

PMID:
29477021
32.

Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry.

Lee I, Kaminski HJ, Xin H, Cutter G.

Muscle Nerve. 2018 Feb 21. doi: 10.1002/mus.26104. [Epub ahead of print]

PMID:
29466829
33.

Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study.

Murphy SL, Barber MW, Homer K, Dodge C, Cutter GR, Khanna D.

Arthritis Care Res (Hoboken). 2018 Nov;70(11):1653-1660. doi: 10.1002/acr.23522.

PMID:
29381834
34.

National estimates of self-reported sitting time in adults with multiple sclerosis.

Sasaki JE, Motl RW, Cutter G, Marrie RA, Tyry T, Salter A.

Mult Scler J Exp Transl Clin. 2018 Jan 19;4(1):2055217318754368. doi: 10.1177/2055217318754368. eCollection 2018 Jan-Mar.

35.

Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE.

Hussain RZ, Miller-Little WA, Doelger R, Cutter GR, Loof N, Cravens PD, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e437. doi: 10.1212/NXI.0000000000000437. eCollection 2018 Mar.

36.

A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression.

Iacoviello BM, Murrough JW, Hoch MM, Huryk KM, Collins KA, Cutter GR, Iosifescu DV, Charney DS.

NPJ Digit Med. 2018;1. pii: 21. doi: 10.1038/s41746-018-0025-5. Epub 2018 Jun 6.

37.

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Wang G, Marrie RA, Fox RJ, Tyry T, Cofield SS, Cutter GR, Salter A.

Mult Scler Relat Disord. 2018 Feb;20:16-21. doi: 10.1016/j.msard.2017.12.006. Epub 2017 Dec 14.

PMID:
29275057
38.

Neurofibromatosis Clinical Trial Consortium.

Packer RJ, Fisher MJ, Cutter G, Cole-Plourde K, Korf BR.

J Child Neurol. 2018 Jan;33(1):82-91. doi: 10.1177/0883073817739196. Review.

PMID:
29246097
39.

Accuracy of Blood Pressure Measurement Devices in Pregnancy: A Systematic Review of Validation Studies.

Bello NA, Woolley JJ, Cleary KL, Falzon L, Alpert BS, Oparil S, Cutter G, Wapner R, Muntner P, Tita AT, Shimbo D.

Hypertension. 2018 Feb;71(2):326-335. doi: 10.1161/HYPERTENSIONAHA.117.10295. Epub 2017 Dec 11. Review.

40.

Diet quality is associated with disability and symptom severity in multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox R, Marrie RA.

Neurology. 2018 Jan 2;90(1):e1-e11. doi: 10.1212/WNL.0000000000004768. Epub 2017 Dec 6.

PMID:
29212827
41.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, Marrie RA.

Neurol Clin Pract. 2017 Aug;7(4):333-343. doi: 10.1212/CPJ.0000000000000383.

42.

A Randomized Trial of an Advanced Sun Safety Intervention for Vacationers at 41 North American Resorts.

Andersen PA, Buller DB, Walkosz BJ, Scott MD, Beck L, Liu X, Abbott A, Eye R, Cutter G.

J Health Commun. 2017 Dec;22(12):951-963. doi: 10.1080/10810730.2017.1382615. Epub 2017 Nov 21.

43.

Prevalence of Sun Protection at Outdoor Recreation and Leisure Venues at Resorts in North America.

Walkosz BJ, Scott MD, Buller DB, Andersen PA, Beck L, Cutter GR.

Am J Health Educ. 2017;48(2):90-99. doi: 10.1080/19325037.2016.1271755. Epub 2017 Mar 10.

44.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

45.

Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis.

Fallata A, Salter A, Tyry T, Cutter GR, Marrie RA.

Int J MS Care. 2017 Sep-Oct;19(5):240-246. doi: 10.7224/1537-2073.2016-065.

46.

Learning from the past: reflections on recently completed myasthenia gravis trials.

Benatar M, Howard JF Jr, Barohn R, Wolfe GI, Cutter G.

Ann N Y Acad Sci. 2018 Jan;1412(1):5-13. doi: 10.1111/nyas.13501. Epub 2017 Oct 24.

47.

Clinical trial design for progressive MS trials.

Pardini M, Cutter G, Sormani MP.

Mult Scler. 2017 Oct;23(12):1642-1648. doi: 10.1177/1352458517729461. Review.

PMID:
29041873
48.

Coastal ocean and shelf-sea biogeochemical cycling of trace elements and isotopes: lessons learned from GEOTRACES.

Charette MA, Lam PJ, Lohan MC, Kwon EY, Hatje V, Jeandel C, Shiller AM, Cutter GA, Thomas A, Boyd PW, Homoky WB, Milne A, Thomas H, Andersson PS, Porcelli D, Tanaka T, Geibert W, Dehairs F, Garcia-Orellana J.

Philos Trans A Math Phys Eng Sci. 2016 Nov 28;374(2081). pii: 20160076. doi: 10.1098/rsta.2016.0076. Review.

49.

Pedestrian safety in patients with Parkinson's disease: A case-control study.

Ford KJ, Joop A, Memon RA, Wood KH, Ball K, Cutter GR, Schwebel DC, Amara AW.

Mov Disord. 2017 Dec;32(12):1748-1755. doi: 10.1002/mds.27124. Epub 2017 Oct 4.

50.

Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Fox RJ.

Neurology. 2017 Sep 26;89(13):1429-1430. doi: 10.1212/WNL.0000000000004437. No abstract available.

PMID:
28947584

Supplemental Content

Loading ...
Support Center